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Conclusion: Infection is a risk factor for venous thromboembolism
(VTE).
Summary: Rates of acute infections and acute venous thromboembo-
lism (VTE) are both high; therefore, any relationship between infection and
VTE has potential major clinical importance. Evidence is emerging of
a possible relationship between deep venous thrombosis, pulmonary embo-
lism, and acute infection (Smeeth L et al, Lancet 2006;367:1075-9; and
Clayton TS, Int J Epidemiol 2011;40:819-27). Studies to date, however,
have not examined the magnitude and duration of the potential increase
of VTE risk associated with hospital-acquired or community-acquired infec-
tions. The authors examined whether patients with hospital-diagnosed or
community-treated infection were at increased risk of VTE. This was a pop-
ulation-based, case-controlled study in northern Denmark encompassing
a population of 1.8 million. Data were obtained from medical databases.
All patients with a ﬁrst hospital-diagnosed VTE during the period 1999
to 2009 (n ¼ 15,009) were included. For each VTE case, 10 controls
from the general population were selected and matched for age, sex, and
county of residence (n ¼ 150,074). All hospital-diagnosed infections and
community prescriptions for antibiotics 1 year predating VTE were identi-
ﬁed. Odds ratios from a conditional logistic regression model were used
to estimate incident rate ratios (IRRs) of VTE within different time intervals
of the ﬁrst year after infection while controlling for compounding variables.
The authors found urinary tract, skin, intra-abdominal, respiratory, and
bacterial infections diagnosed in the hospital or treated in the community
were associated with a twofold or more increased VTE risk. VTE risk was
strongest within the ﬁrst 2 weeks after infection and then gradually declined.
Compared with individuals without infection during the year before VTE,
the IRR (95% conﬁdence interval) for VTE within the ﬁrst 3 months after
infection was 12.5 (11.3-13.9) for patients with hospital-diagnosed infec-
tion and 4.0 (3.8-4.1) for patients treated with antibiotics in the community
setting. IRRs (95% conﬁdence interval) were decreased after adjustment for
VTE risk factors to 3.3 (2.9-3.8) for hospital-acquired infection and to
2.6 (2.5-2.8) for community-acquired infections treated with antibiotics.
Associations were similar for unprovoked VTE, deep venous thrombosis,
and pulmonary embolism individually.
Comment: Infection is clearly emerging as a risk factor for VTE. The
primary contribution of this report is its suggestion that this increased risk of
VTE induced by infection is greatest within the ﬁrst 2 weeks after infection
onset. It follows there may be clinical circumstances in which patients with
acute infections, particularly those with other signiﬁcant VTE risk factors,
should be considered for VTE prophylaxis, at least for the ﬁrst month after
the onset of infection. A great deal of additional work remains to be per-
formed to determine precisely what types of infections, what severity of
infection, and in what particular patient subgroups such a policy of
enhanced prophylaxis could be both clinically effective and cost effective.Association of Mild to Moderate Chronic Kidney Disease With Venous
Thromboembolism Pooled Analysis of Five Prospective General
Population Cohorts
Mahmoodi BK, Ganesvoort RT, Naess IA, et al. Circulation 2012;126:
1964-71.
Conclusion: Estimated glomerular ﬁltration rate (eGFR) and
albumin-to-creatinine ratio (ACR) are both independently associated with
an increased risk of venous thromboembolism (VTE) in the general popu-
lation. This risk even holds across eGFR and ACR levels within normal
reference ranges.
Summary: In up to 50% of patients with VTE there are no known
VTE risk factors present (White RH, Circulation 2003;107:I4-8). However,
nephrotic syndrome and overt proteinuria are known risk factors for VTE
(Mahmoodi BK et al, Circulation 2008;117:224-30). This may reﬂect
that even mild to moderate chronic kidney disease (CKD) can be associated
with a procoagulant state (Dubin R, BMC Nephrol 2011;12:3). Because
there is a high prevalence of CKD in the general adult population
(10%-16%) and high numbers of VTE events yearly, the authors felt an in-600depth analysis of the association of CKDwith VTE was warranted. This study
pooled individual participant data from ﬁve community-based cohorts (three
from Europe and two from the United States). The European studies
included the second Nord-Trondelag Health Study, Prevention of Renal
and Vascular End-stage Disease Study, and the Tromso study. The United
States studies included the Atherosclerosis Risk in Communities (ARIC)
study and the Cardiovascular Health Study. Associations were determined
among eGFR, albuminuria, and CKD with objectively veriﬁed VTE.
Adjusted hazard ratios for VTE were estimated using categoric and contin-
uous spline models ﬁt by using Cox regression with shared-frailty or
random-effect meta-analysis. There were 1178 VTE events recorded during
599,453 person-years of follow-up. Relative to eGFR 100 mL/min/
1.73 m2, hazard ratios (95% conﬁdence interval) for VTE were 1.29
(1.04-1.59) for eGFR 75, 1.31 (1.00-1.71) for eGFR 60, 1.82 (1.27-
2.60) for eGFR 45, and 1.95 (1.26-3.01) for eGFR at 30 mL/min/
1.73 m2. A comparison with an ACR of 5 mg/g, found hazards ratios for
VTE were 1.34 (1.04-1.72) for ACR at 30, 1.60 (1.08-2.36) for ACR at
300, and 1.92 (1.19-3.08) for ACR at 1000mg/g. No interaction was found
between clinical categories of eGFR and ACR (P¼ .20). The adjusted hazard
ratio for CKD, deﬁned as eGFR <60 mL/min/1.73 m2 or albuminuria
$30 mg/g vs no CKD was 1.54 (1.15-2.06). Associations remained consis-
tent in subgroups with respect to sex, age, and comorbidities as well as
provoked vs unprovoked VTE.
Comment: Clearly, CKD and VTE are both common. This study
suggests, on a population basis, that even a small amount of CKD may
predispose to VTE. The authors note that the effect size of the association
may limit individual level implications. However, risk factors for VTE
frequently act in what is essentially an exponential fashion. Therefore,
even a small individually isolated effect of CKD, when combined with other
risk factors for VTE, may prove to be clinically important. Increasing greater
appreciation of risk factors for VTE and recurrent VTE should eventually
lead to more personalized determination of levels and durations of anticoa-
gulation for VTE and more directed prophylaxis for VTE in the at-risk
patient.Clopidogrel and the Risk of Osteoporotic Fractures: A Nationwide
Cohort Study
Jorgensen NR, Grove EL, Schwarz P, et al. J Intern Med 2012;272:385-93.
Conclusion: A biphasic relationship exists between the risk of frac-
tures and use of clopidogrel, with lower doses associated with decreased
facture risk and higher doses associated with increased risk.
Summary: Clopidogrel is a thienopyridine drug. The thienopyridine
drugs irreversibly inhibit P2Y12 receptor. P2Y12 belongs to a family of
G-proteinecoupled P2 purinergic, nucleotide-activated receptors (Ralevic
V et al, Pharmacol Rev 1998;50:143-92). The P2Y12 receptor is expressed
in osteoblastic cells, providing at least one mechanism for potential thieno-
pyridine toxic effects on bone cell recruitment, proliferation, and differenti-
ation (Porto I et al, Expert Opin Investig Drgs 2009;18:1317-32). Given
the potential toxic effects of clopidogrel on bone metabolism, the authors
sought to investigate the association between clopidogrel use and the risk
of fractures. This was a nationwide cohort study in Denmark of w5.3
million people that included the 77,503 patients prescribed clopidogrel
from 1996 to 2008. Nonusers of clopidogrel were randomly selected and
matched for age and sex (n ¼ 232,510). The relative risk of any fracture
and osteoporotic fractures was calculated for each clopidogrel-treated
patient and compared with the “control” patients. Table 2 from the manu-
script demonstrates that the relative risk of any fracture or an osteoporotic
fracture, “deﬁned as a hip, spine or forearm fracture,” was reduced for indi-
viduals exposed to low doses of clopidogrel but was increased in patients
treated with higher doses of clopidogrel, even within the recommended
dose range. During follow-up, individuals with low exposure to clopidogrel
(<0.01 deﬁned daily dose) had a lower risk of fractures than nonusers of
clopidogrel.
Comment: It is actually unclear how important the P2Y12 receptor is
in bone metabolism. The mechanisms whereby clopidogrel affects bone
turnover remain largely unknown. However, newer and even more potent
antiplatelet drugs such as prasugrel and ticagrelor could conceivably have
increased greater fracture risk over that of clopidogrel. The overall contribu-
tion of patient morbidity through potentially clopidogrel-facilitated
